このエントリーをはてなブックマークに追加
ID 49383
FullText URL
Thumnail 125_41.pdf 7.49 MB
Title Alternative
A case of gastrointestinal stromal tumor with synchronous liver metastases showing long-term disease control by imatinib
Author
Uno, Futoshi
Fujiwara, Yasuhiro
Abstract
 Radical surgery is the primary treatment for gastrointestinal stromal tumor (GIST), so that unrsectable GIST has been considered a fatal disease, and the median duration of survival for patients with an unresectable GIST before the era of molecular targeted therapy has been about 18 months. Since the recent development of agents for molecular targeted therapy, including imatinib mesylate, the prognosis of unrsectable GIST has been dramatically improved. The B2222 trial reported that a median time to progression and a median overall survival for advanced GIST treated with imatinib of 24 months and 57 months, respectively. We recently experienced a case of gastrointestinal stromal tumor with synchronous liver metastases maintained in whom the disease was controlled for 4 years by imatinib. The patient is 37-year-old man and he took imatinib mesylate at 400mg/day with no adverse events. Both primary and metastases lesions responded well to imatinib treatment, and this efficacy has endured for 4 years, such that surgical intervention is now considered possible. While GIST is a relatively rare disease and clinical evidence is still poor, we document our considerations for the therapy in this case as well as the results.
Keywords
イマチニブ(imatinib)
GIST
Note
症例報告(Case Report)
Published Date
2013-04-01
Publication Title
岡山医学会雑誌
Publication Title Alternative
Journal of Okayama Medical Association
Volume
volume125
Issue
issue1
Publisher
岡山医学会
Publisher Alternative
Okayama Medical Association
Start Page
41
End Page
45
ISSN
0030-1558
NCID
AN00032489
Content Type
Journal Article
Related Url
http://www.okayama-u.ac.jp/user/oma/
References
1) Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, et al. : Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 26, 620-625.
2) GIST診療ガイドライン 2010年11月改訂(第2版補訂版), 日本癌治療学会, 日本胃癌学会, GIST研究会編, 金原出版, 東京(2010).
3) DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF : Two hundred gastrointestinal stromal tumors : recurrence patterns and prognostic factors for survival. Ann Surg (2000) 231, 51-58.
4) E Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, et al. : Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 347, 472-480.
5) Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A, Emile JF, Chabaud S, et al. : Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment : an open-label multicentre randomised phase 3 trial. Lancet Oncol (2010) 11, 942-949.
6) Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM : Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol (2006) 24, 2325-2331.
7) 大西一功 : Imatinib mesylate投与の実際と注意すべき薬物有害反応. 血液・腫瘍科(2003)46, 40-44.
8) Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, et al. : Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 21, 4342-4349.
9) Lasota J, Miettinen M : Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology (2008) 53, 245-266.
10) Nishida T, Takahashi T, Miyazaki Y : Gastrointestinal stromal tumor : a bridge between bench and bedside. Gastric Cancer (2010) 12, 175-188.
language
日本語
Copyright Holders
Copyright (c) 2013 岡山医学会
File Version
publisher
Refereed
True
DOI
Eprints Journal Name
joma